`l_LJt=ENTif:i
`R/:..N i f.'317..U/v'l.t;,, [•1
`Business Use Only
`
`Lucentis PFS (RFB002)
`
`TRD SubTeam meeting
`
`Meeting Date: Jan . 9, 2011
`Meeting Notes Date: January 18, 2012
`and Team
`Author:
`Room: WSJ-340.3.09
`Dial-in:
`
`Executive Summary
`
`Lucentis CMC Sub Team Meeting Agenda, Meeting Date: January 09, 2012
`
`1 of 5
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2071.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Discussion & Decisions
`
`A enda
`I
`
`-■I
`
`I
`
`I
`
`-■
`
`Lucentis CMC Sub Team Meeting Agenda, Meeting Date: January 09, 2012
`
`2of 5
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2071.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`I
`
`Lucentis CMC Sub Team Meeting Agenda, Meeting Date: January 09, 2012
`
`3 of 5
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2071.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Action Plan:
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2071.004
`Regeneron v. Novartis, IPR2021 -00816
`
`
`
`------HI LF
`
`Lucentis CMC Sub Team Meeting Agenda, Meeting Date: January 09, 2012
`
`5 of 5
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2071.005
`Regeneron v. Novartis, IPR2021-00816
`
`